Q2 FY2026 EarningsQ2 FY2026 results showed a revenue beat of $9.26M vs. $8.60M expected, although top-line growth declined 1.6% YoY due to terminated distribution agreements. Operating loss of $1.61M was significantly worse than the expected $0.76M, as gross margins compressed to 26.2% from 36.4% YoY. GAAP EPS of -$1.15 beat the consensus of -$1.20, primarily driven by a 203.6% increase in the weighted average share count following substantial equity financing and warrant exercises.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Sunshine Biopharma(SBFM) the Revenue is 9.264 M (-1.56%), Beat estimate;the EBIT is -1.613 M (+21.5%), Miss estimate;the EPS is -1.15 (+70.51%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.01B1.56%
0.01B8.61%
+0.00B7.05%
EBITMiss expectations
-0.00B21.50%
-0.00B63.01%
-0.00B41.51%
EPSExceed expectations
-1.1570.51%
-1.269.23%
+0.05001.28%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf